Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Chlamydia Infection Diagnostics and Therapeutics Market: By Diagnostics, By Therapeutics Others), By End-user Geography
Chlamydia Infection Diagnostics and Therapeutics Market: By Diagnostics, By Therapeutics Others), By End-user Geography
Chlamydia Infection Diagnostics And Therapeutics Market size was valued at US$ 2.6 billion in 2023 and is poised to grow at a CAGR of 6.1% from 2024-2030. Chlamydia is a sexually transmitted disease (STD) caused by the bacteria Chlamydia trachomatis, and it can be transmitted to a baby at birth. chlamydia infection diagnostics and therapeutics market usually does not have any symptoms but often infected may have symptoms such as genital pain and genital discharge both in men and women. Furthermore, chlamydia infection can cause health complications such as preventing women from getting pregnant or even endangering their pregnancies. Some people may experience pain in the lower abdomen, pelvis, testicle, or vagina and may also have eye discharge or spotting. Treatment may include antibiotics and anti-inflammatory agents, and a hospital stay may be required.
The global chlamydia infection diagnostics and therapeutics market is growing at significant rates owing to the prevalence rate of sexually transmitted diseases. According to the World Health Organization (WHO), worldwide, more than one million sexually transmitted infections are acquired every day. Each year, an estimated of 131 million new cases of chlamydia infection are reported. Companies are focusing on the development of new ways to detect chlamydia infection in the initial stages. For instance, in December 2016, F. Hoffmann-La Roche AG launched Cobas 6800/8800 systems for the detection of Chlamydia trachomatis and Neisseria Gonorrhoea (NG) DNA.
Study Period
2024-2030Base Year
2023CAGR
6.1%Largest Market
North AmericaFastest Growing Market
North-America
Global chlamydia infection diagnostics and therapeutics market is mainly driven by an increase in prevalence of sexually transmitted diseases worldwide. Furthermore, emergence of rapid test and advances in biotechnology are expected to boost the chlamydia infection diagnostics and therapeutics market. In addition, increase in R&D activities towards development of therapeutics for antibiotic-resistant bacteria and initiatives by government and non-government agencies (such as World Health Organization (WHO) to increase awareness about STD and their symptoms are expected to bolster the chlamydia diagnostics and therapeutics market during the forecast period. However, high cost of development, stringent regulatory procedures for the approval and bacterial drug resistance is expected to hamper the chlamydia infection diagnostics and therapeutics market.
North America market is expected to grow at significant rates owing to well-established healthcare infrastructure, the presence of more market players, and an increase in awareness related to early detection and treatment of sexually transmitted diseases. According to the Centre for Disease Control and Prevention (CDC) in 2014, a total number of 1,441,789 chlamydia infections were reported to CDC in 50 states and the District of Columbia in the United States. Europe's chlamydia infection diagnostics and therapeutics market is expected to grow at notable rates owing to factors such as developed healthcare infrastructure and growing awareness related to STIs. Asia Pacific market growth is attributed to developing infrastructure and prevalence of the chlamydia sexually transmitted diseases. According to the World Health Organization, the Global incidence and prevalence of selected curable sexually transmitted infections in the South East Asia region estimated that 8 million adults were infected with Chlamydia in 2008.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 2.6 billion |
|
Market CAGR |
6.1% |
|
By Diagnostics |
|
|
By Therapeutics |
|
|
By End-user |
|
Download Free Sample Report
The global chlamydia infection diagnostics and therapeutics market size was valued at US$ 2.6 billion in 2023 and is projected to grow at a CAGR of 6.1% from 2024-2030
Abbott Laboratories, Bio-Rad Laboratories Inc, Becton Dickinson and Company, bioMérieux, DiaSorin SpA
North America is the fastest-growing region for chlamydia infection diagnostics and therapeutics market
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.